Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

92.18 -0.06 (-0.07%)
Streaming Delayed Price Updated: 2:52 PM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc... 
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal... 
Via Stocktwits
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗
Via Chartmill
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive... 
Via StockStory
Topics Stocks
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong... 
Via StockStory
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Nosediving
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.8% in the morning session after the company reported mixed fourth-quarter 2025 results, where a significant revenue beat was... 
Via StockStory
Topics Artificial Intelligence Earnings
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Incyte (INCY) Q4 2025 Earnings Call Transcript ↗
Incyte (INCY) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte (INCY) Q4 Earnings: What To Expect
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday before market open. Here’s what to look for. 
Via StockStory
Topics World Trade
News headline image
2 Profitable Stocks Worth Investigating and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
2 Value Stocks Worth Investigating and 1 That Underwhelm
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful... 
Via StockStory
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
3 Value Stocks Worth Investigating
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Credit Cards
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.